Contacts | Age | Vaccine | Route of administration | Preventable diseases |
---|---|---|---|---|
1st contact | At birth | BCG | Intradermal | Tuberculosis |
OPV 0 | Oral | Poliomyelitis | ||
2nd contact | 6 weeks | DTP-HepB-Hib 1 | Intramuscular | Diphteria, Tetanus, Pertussis,Infection due to Haemophilus Influenzae type b, Hepatitis B |
OPV 1 | Oral | Poliomyelitis | ||
Pneumo 13–1 (PCV) | Intramuscular | Pneumococcal infections | ||
ROTA 1 | Oral | Rotavirus Diarrhoea | ||
3rd contact | 10 weeks | DTP-HepB-Hib 2 | Intramuscular | Diphteria, Tetanus, Pertussis,Infection due to Haemophilus Influenzae type b, Hepatitis B |
OPV 2 | Oral | Poliomyelitis | ||
Pneumo 13–2 ROTA 2 | Intramuscular Oral | Pneumococcal infections Rotavirus Diarrhoea | ||
4th contact | 14 weeks | DTP-HepB-Hib 3 | Intramuscular | Diphteria, Tetanus, Pertussis,Infection due to Haemophilus Influenzae type b, Hepatitis B |
OPV 3 IPV | Oral Intramuscular | Poliomyelitis | ||
Pneumo 13–3 | Intramuscular | Pneumococcal infections | ||
5th contact | 6 to 11 months | Vit A | Oral | |
At 9 months | MR | Subcutaneous | Measles, Rubella | |
YF | Subcutaneous | Yellow fever |